AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00432484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lingzhi and Sen Miao San
Description: G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
Study NCT02386020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aloe vera
Description: After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
Study NCT02386020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: After SRP, placebo gel was delivered subgingivally into periodontal pockets.
Study NCT04607486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3DfUS and IPSA of leg muscles
Description: 1. 3DfUS technique enhances a conventional 2D US device into a platform capable of reconstructing 3D anatomical data sets.~2. IPSA for quantification of hyper-resistance and its underlying components. The sensors in the IPSa include gyroscopes and accelerometers to measure joint angle and angular velocity, EMG to measure muscle activity, and a 3 degrees-of freedom force sensor to measure torque applied on the joint.~3. clinical functional capacity = clinical evaluation of degree of independence, mobility and gait
Study NCT01519323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Cohort 1 (participants >=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants \<45 kg): starting dose 480 mg
Study NCT01411826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information + Narratives + Support Group
Description: Information from CDC website Narratives about CRCS written by others Peer social support among study participants
Study NCT01411826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: Information from CDC website on colon cancer screening.
Study NCT05378685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: The patient is intubated using a laryngoscope and cuffed endotracheal tube. The selection and size of the equipment is at the discretion of the pediatric cardiac anesthesiologist.
Study NCT01157702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (split virus, Vero cell-derived)
Description: One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
Study NCT04046328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Cholestyramine (ECC) Capsule
Description: Enteric-Coated Delayed Release Cholestyramine Capsules
Study NCT04046328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Enteric-Coated Delayed Release Placebo Capsules
Study NCT00301808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
Study NCT00301808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 on day 1 of each cycle
Study NCT00301808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed disodium
Description: Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
Study NCT00301808 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
Study NCT02544321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Study NCT02544321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01657851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dutasteride
Description: Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
Study NCT00591682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSX-122
Description: Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~* If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~* If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~* If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort.
Study NCT01582815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
Study NCT01582815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
Study NCT05450367 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study NCT04441359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemented formula
Description: standard infant formula supplemented with 8 g/L prebiotic inulin-type fructans
Study NCT04441359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard formula
Description: standard infant formula not supplemented with prebiotic inulin-type fructans
Study NCT03290443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: 100 mg enasidenib (CC-90007)
Study NCT04532307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care SOC
Description: Research assistants refer the consenting participants to Isisekelo Sempilo adolescent and youth friendly services with HIV testing, treatment if positive and PrEP eligibility screening and offer if negative and family planning
Study NCT04532307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SRH enhanced Isisekelo Sempilo
Description: Self-collected vaginal and urine samples are collected at enrolment. Research assistants then provide an Isisekelo Sempilo clinic referral appointment for results, treatment, HIV testing, sexual health, fertility, and family planning counselling, including the personal benefits of ART and Undetectable=Uninfectious among those infected, and PrEP for those eligible and who are negative.
Study NCT04532307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-support (Thetha-Nami)
Description: The research assistants refer the participant to a Thetha Nami peer-navigator in their community. Peer navigators will assess their health, social and educational needs, provide mentorship, and help them access the services they need. The peer navigator will facilitate attendance, adherence and retention at the Isisekelo Sempilo clinic.
Study NCT04532307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC + SRH + peer-support
Description: A combination of interventions 2 and 3, to include both self-collected STI testing, nurse led testing and counseling, and referral to a Thetha Nami peer navigator to encourage clinic attendance and sexual health promotion.
Study NCT03441438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Serum and urine markers will be obtained after drinking 5 oz of water
Study NCT03441438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red wine
Description: Serum and urine markers will be obtained after drinking 5 oz of water
Study NCT03441438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenolic Compounds
Description: Serum and urine markers will be obtained after consuming 100 mg of provinols powder
Study NCT04889846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAFE early intervention approach
Description: SAFE approach is a national early intervention approach which is based on sensory strategies, activity based motor training, family collaboration and environmental enrichment.
Study NCT03149055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PD-L1 antibody
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Anti CTLA-4 antibody
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV administered chemotherapy
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: orally-administered chemotherapy
Study NCT02735239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV administered chemotherapy
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV administered Chemotherapy
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: IV administered chemotherapy
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: chemo-protective agent
Study NCT02735239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV administered chemotherapy
Study NCT01406886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating rate
Study NCT00948753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 150 MG
Description: Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
Study NCT01657851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin
Description: Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
Study NCT00948753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
Study NCT00948753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg Phase II
Description: Maraviroc b.i.d. (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stem-cell infusion.
Study NCT01453049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone/glimepiride fix dose combination
Description: oral, once daily, dosage is titrated according to FPG and hypoglycemia events
Study NCT01453049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: oral, once daily, dosage is titrated according to FPG and hypoglycemia
Study NCT03327909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAKE vs. HOLD
Description: All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
Study NCT00683878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
Study NCT00683878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
Study NCT00683878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Dapagliflozin
Description: Tablets, Oral, 0 mg, once daily, up to 48 weeks
Study NCT00683878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (Pioglitazone)
Description: Tablets, ≥ 30 mg, Once daily, up to 48 weeks
Study NCT00683878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiazolidinedione (Pioglitazone)
Description: Tablets, ≥ 30 mg, Once daily, up to 48 weeks
Study NCT02773381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once-daily.
Study NCT02773381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration once-daily.
Study NCT04355234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: identify SARS-CoV-2 infection by serology
Description: Blood samples at delivery to identify SARS-CoV-2 infection by serology
Study NCT04355234 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collection of biological samples
Description: Creation of a specific collection of biological samples for new investigations thanks to the collection of several biological samples at the time of maternal SARS-CoV-2 infection, at delivery and in the postpartum period in the parturient and her newborn.
Study NCT03481894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kabiven®
Description: Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Study NCT03481894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compounded standard parenteral nutrition
Description: Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy.
Study NCT00453154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00453154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT00453154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00453154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT00453154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00453154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT00453154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00453154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00453154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT00453154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT03392103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: concurrent chemotherapy
Study NCT03392103 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiotherapy
Description: concurrent postoperative radiation therapy
Study NCT02907034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality experimentation sequency (VR)
Study NCT02907034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality experimentation sequency (VR)
Study NCT02907034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classical narrative approach (CN)
Study NCT02907034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical narrative approach (CN)
Study NCT02680522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: exercise training with virtual reality in videogame
Study NCT02680522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: exercise training with virtual reality in videogame
Study NCT01693029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 epoetin alfa
Description: Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
Study NCT01693029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed epoetin alfa
Description: Solution for subcutaneous injection.
Study NCT00983307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
Study NCT00983307 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Patients undergo hypofractionated thoracic RT 5 days a week for approximately 2.5 weeks beginning on day 0. Patients also receive erlotinib hydrochloride PO daily beginning on day -5 and continuing for up to 24 months in the absence of disease progression or unacceptable toxicity.
Study NCT04601935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-BCX cells product
Description: In this study, LCAR-BCX CAR+ cells will be evaluated at 5 dose levels including 0.25 × 10\^6 cells/kg, 0.5 × 10\^6 cells/kg, 1.0 × 10\^6 cells/kg, 2.0 × 10\^6 cells/kg, and 4.0 × 10\^6 cells/kg, with 0.25 × 10\^6 cells/kg as the starting dose, to determine RP2D for LCAR-BCX cell therapy
Study NCT04956536 — intervention group
Intervention type: OTHER
Intervention: Demographic data and MRI images were extracted and analyzed
Description: Demographic data and MRI images were extracted and analyzed. Related factors for anterior tibial subluxation were examined in anterior cruciate ligament-injured patients.
Study NCT01057953 — intervention group
Intervention type: GENETIC
Group type: NO_INTERVENTION
Intervention: Blood drawn
Description: Blood drawn for patient
Study NCT03614117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius PS7 during 6 months
Description: 7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
Study NCT03614117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius PS7 during 3 months
Description: 7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
Study NCT03614117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
Study NCT00922623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero®
Description: Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer